News - CLSD-News-Wired News – Clearside BioMedical Reported Positive Top-line Results from Phase-3 Trial Assessing CLS-TA in Macular Edema Associated with Non-infectious Uveitis
Volumen 3.5M, Float 18.42M, Avg Vol (10 day) 3.07M, Avg Vol (3 month) 426.32k, NasdaqGM, Healthcare-Biotechnology
Entry 14.25, Stop Loss 14.90, Take profit 12.50, 1D Still green candle# Entry 1m timeframe#Broke trend line#BreakDown#Stock made in 2 days 130%-News (4 News in 2 days-incredible)
Be ready if market make something unpredictable. Stay with your position, carefully!!!